Detailed Information on Publication Record
2023
The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 24th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2022
DUCREUX, M., G. K. ABOU-ALFA, T. BEKAII-SAAB, J. BERLIN, A. CERVANTES et. al.Basic information
Original name
The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 24th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2022
Authors
DUCREUX, M., G. K. ABOU-ALFA, T. BEKAII-SAAB, J. BERLIN, A. CERVANTES, T. DE BAERE, C. ENG, P. GALLE, S. GILL, T. GRUENBERGER, K. HAUSTERMANS, A. LAMARCA, P. LAURENT-PUIG, J. M. LLOVET, F. LORDICK, T. MACARULLA, D. MUKHERJI, K. MURO, Radka LORDICK OBERMANNOVÁ (203 Czech Republic, belonging to the institution), J-M. CONNOR, E. M. REILLY, P. OSTERLUND, P. PHILIP, G. PRAGER, E. RUIZ-GARCIA, B. SANGRO, T. SEUFFERLEIN, J. TABERNERO, C. VERSLYPE, H. WASAN and E. VAN CUTSEM
Edition
ESMO OPEN, AMSTERDAM, ELSEVIER, 2023, 2059-7029
Other information
Language
English
Type of outcome
Článek v odborném periodiku
Field of Study
30204 Oncology
Country of publisher
Netherlands
Confidentiality degree
není předmětem státního či obchodního tajemství
References:
Impact factor
Impact factor: 7.300 in 2022
RIV identification code
RIV/00216224:14110/23:00133415
Organization unit
Faculty of Medicine
UT WoS
001045033500001
Keywords in English
hepatocellular carcinoma; liver transplantation; chemoembolisation; immunotherapy; radioembolisation
Tags
International impact, Reviewed
Změněno: 2/2/2024 10:59, Mgr. Tereza Miškechová
Abstract
V originále
This article summarises expert discussion on the management of patients with hepatocellular carcinoma (HCC), which took place during the 24th World Gastrointestinal Cancer Congress (WGICC) in Barcelona, July 2022. A multidisciplinary approach is mandatory to ensure an optimal diagnosis and staging of HCC, planning of curative and therapeutic options, including surgical, embolisation, ablative strategies, or systemic therapy. Furthermore, in many patients with HCC, underlying liver cirrhosis represents a challenge and influences the therapeutic options.